Razak Clarifies Capacity of New Tablet Line in Updated Filing

Razak Laboratories updated its group A material disclosure on Sunday, October 18, 2026, to clarify the capacity of its second solid-dosage production line after receiving an operating permit. The company put nominal capacity at 360 million tablets and practical capacity at 300 million, saying 150 million could be reached by the end of the Iranian year. It estimated that added production of Lozar, prazosin and cetirizine tablets would affect total sales revenue by about 14%. This is the company's estimate, not realised revenue.